Delving into the Latest Updates on Octenidine dihydrochloride/Hyaluronic acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Stamatological

Target

CD44

Action

modulators

Mechanism

CD44 modulators(CD44 antigen modulators)

Therapeutic Areas

Mouth and Tooth Diseases

Active Indication-

Inactive Indication

Dry Socket

Originator Organization

Contipro Pharma as

Active Organization-

Inactive Organization

Contipro Pharma as

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC36H64Cl2N4

InChIKeySMGTYJPMKXNQFY-UHFFFAOYSA-N

CAS Registry70775-75-6

View All Structures (2)

Alveolar Osteitis (AO) is a complication following extraction of a tooth. AO manifests by localized pain in and around the extraction site where the postoperative blood clot has been disintegrated. The aim of this study was to determinate if there are any concerns of use of a pharmacological drug composed of an octenidine and lyophilized hyaluronic acid in a treatment of AO.
The tested drug is a sponge-like material composed solely of fully absorbable medicaments. It was designed to serve as non-toxic, slow-dissolving antiseptic which adheres to mucosa and so obturate the wound. The treatment was considered effective when the pain subsided to < 20mm VAS in < 8 days of treatment.

Start Date11 Sep 2015

Sponsor / Collaborator

Contipro Pharma as

100 Clinical Results associated with Octenidine dihydrochloride/Hyaluronic acid

Login to view more data

100 Translational Medicine associated with Octenidine dihydrochloride/Hyaluronic acid

Login to view more data

100 Patents (Medical) associated with Octenidine dihydrochloride/Hyaluronic acid

Login to view more data

100 Deals associated with Octenidine dihydrochloride/Hyaluronic acid

Login to view more data